The Food and Drug Administration (FDA) has recently received reports from patients, physicians, and specialty pharmacies that they have been unable to obtain C1-Esterase Inhibitor (Human) Cinryze. Healthcare providers and patients may wish to consider alternate treatment options, including:
For Prophylaxis: Haegarda was recently licensed for prophylaxis of HAE attacks. Haegarda is administered subcutaneously, twice a week. Information about Haegarda, including the prescribing information, is posted on FDA’s web site.
For Treatment: It is important for patients, even those on prophylaxis, to make sure they have rapid access to treat any acute HAE attacks. Four products are licensed for treatment of HAE attacks:
- Berinert (CSL Behring)
- Ruconest (Pharming)
- Firazyr (Shire)
- Kalbitor (Dyax Corporation)
FDA recommends that patients with HAE work closely with their health care professionals. Your doctor is in the best position to assess your medical situation and determine your best course of treatment.
If you have additional questions, please feel free to contact FDA’s Center for Biologics Evaluation and Research by phone at (800) 835-4709, (240) 402-8010, or by email at firstname.lastname@example.org.